A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy
About the study
This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in subjects with hematologic malignancies who have failed standard treatment.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Histologically/cytologically confirmed hematologic malignancy who failed the standard treatment
- At least one evaluable lesion
- Male or female 18 to 75 years old
- Eastern Cooperative Oncology Group Performance Status Performance Status (ECOG PS) 0-2
- Must have adequate organ function
EXCLUSION CRITERIA
Exclusion Criteria:
- Previous exposure to any anti-CD47 monoclonal antibody, SIRPα antibody, or CD47/SIRPα recombinant protein
- Previous exposure to chimeric antigen receptor T cell immunotherapy (CAR-T)
- Subjects participating in another interventional clinical study, except for: observational (non-interventional) clinical studies or survival follow-up phase of interventional studies
- Use of anticoagulants and/or aspirin, or other non-steroidal anti-inflammatory drugs within 2 weeks prior to study start
- A history of blood transfusion within 2 weeks prior to study start
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Hematologic Malignancy
Age (in years)
18 - 75
Phase
Phase 1
Participants needed
230
Est. Completion Date
Apr 30, 2024
Treatment type
Interventional
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
ClinicalTrials.gov identifier
NCT04795128
Study number
CIBI322A103
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?